Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Briacell Therapeutics Corp. T.BCT

Alternate Symbol(s):  BCTX | BCTXW

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II... see more

Recent & Breaking News (TSX:BCT)

BriaCell Therapeutics Corp. Announces Completion of Shares for Debt Issuance

GlobeNewswire August 17, 2020

BriaCell Presents Clinical and Scientific Findings at the Annual Symposium of Society of Surgical Oncology 2020

GlobeNewswire August 17, 2020

Briacell Therapeutics Corp. Announces Shares for Debt Issuance

GlobeNewswire August 11, 2020

BriaCell Files Provisional Patent Application for Novel Treatment and Diagnosis of Coronavirus Disease

GlobeNewswire June 24, 2020

BriaCell Announces Presentation of Clinical and Scientific Findings at AACR Annual Meeting

GlobeNewswire June 22, 2020

BriaCell CEO to Present at 3rd Annual Next-Gen Immuno-Oncology Congress in June

GlobeNewswire June 9, 2020

BriaCell Presents Clinical Findings at 2020 American Society of Clinical Oncology (ASCO) Meeting

GlobeNewswire May 29, 2020

BriaCell Files Patent Application for Novel Immune Therapies for Multiple Disease Indications

GlobeNewswire May 20, 2020

BriaCell Announces Presentation and Abstract Publication at 2020 American Society of Clinical Oncology (ASCO) Meeting

GlobeNewswire May 14, 2020

BriaCell Continues Business and Clinical Operations During COVID-19 Pandemic

GlobeNewswire May 12, 2020

BriaCell Files Patent Application for Novel Therapeutics for Cancer

GlobeNewswire April 27, 2020

BriaCell Files New Provisional Patent Application for Antibody-Based Treatment of Infectious Diseases

GlobeNewswire April 21, 2020

UPDATE - BriaCell Files Coronavirus Immunotherapy Patent

GlobeNewswire April 14, 2020

BriaCell Files Coronavirus Immunotherapy Patent

GlobeNewswire April 14, 2020

BriaCell to Present Clinical Data at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting May 29

GlobeNewswire March 31, 2020

BriaCell Continues Clinical Operations Amidst COVID-19 Pandemic

GlobeNewswire March 26, 2020

BriaCell to Present Clinical and Immune Activity at AACR Annual Meeting

GlobeNewswire February 26, 2020

BriaCell Announces Proposed Public Offering in the United States and Listing on NASDAQ

GlobeNewswire February 21, 2020

BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center - Jefferson Health for Phase I/IIa Combination Study of Bria-IMT(TM)

GlobeNewswire February 11, 2020

BriaCell's Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston

GlobeNewswire January 28, 2020